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Background: We recently identified U1 small nuclear ribonucleoprotein (snRNP) tangle-like aggregates and RNA
splicing abnormalities in sporadic Alzheimer’s disease (AD). However little is known about snRNP biology in early
onset AD due to autosomal dominant genetic mutations or trisomy 21 in Down syndrome. Therefore we
investigated snRNP biochemical and pathologic features in these disorders.
Findings: We performed quantitative proteomics and immunohistochemistry in postmortem brain from genetic
AD cases. Electron microscopy was used to characterize ultrastructural features of pathologic aggregates. U1-70k
and other snRNPs were biochemically enriched in the insoluble fraction of human brain from subjects with
presenilin 1 (PS1) mutations. Aggregates of U1 snRNP-immunoreactivity formed cytoplasmic tangle-like structures in
cortex of AD subjects with PS1 and amyloid precursor protein (APP) mutations as well as trisomy 21. Ultrastructural
analysis with electron microscopy in an APP mutation case demonstrated snRNP immunogold labeling of paired
helical filaments (PHF).
Conclusions: These studies identify U1 snRNP pathologic changes in brain of early onset genetic forms of AD.
Since dominant genetic mutations and trisomy 21 result in dysfunctional amyloid processing, the findings suggest
that aberrant β-amyloid processing may influence U1 snRNP aggregate formation.
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proteinFindings
With age as the greatest risk factor, AD represents a
growing challenge in our aging population. AD research
over the past few decades has focused on cholinergic
dysfunction [1] and its main pathologic constituents:
hyperphosphorylated tau and β-amyloid [2]. Thus far,
clinical trials of disease modifying therapies targeting
these classic markers have been disappointing, and only
modest symptomatic therapies are currently available for* Correspondence: jlah@emory.edu
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unless otherwise stated.patients. Further understanding of AD pathogenesis is
needed in order to develop viable therapies.
We recently identified enrichment of U1 snRNPs,
ribonucleic acid (RNA) processing components, in the
insoluble protein fraction in sporadic AD using an
unbiased quantitative proteomics approach [3]. RNA
splicing is an essential cellular process for converting
precursor messenger ribonucleic acid (pre-mRNA) into
mature mRNA for use in protein translation [4-6]. RNA
processing allows for multiple mRNA and protein
isoforms to be created from the same transcript thus
increasing genetic heterogeneity. Changes in alternative
splicing have been associated with neurodegeneration
[7] including AD [8,9].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with immunoblotting and immunohistochemistry that
showed accumulation of insoluble U1 snRNP tangle-like
structures which partially localized with phospho-tau
positive neurofibrillary tangles in prodromal and early
stage sporadic AD [3]. Furthermore, RNA sequencing tech-
niques demonstrated widespread RNA splicing dysfunction,
including effects on several AD associated genes such as
bridging integrator 1 (BIN1) [10], clusterin [11] and preseni-
lin 1 (PS1) [12]. It remains unknown whether the U1 snRNP
pathological aggregates are present in genetic forms of
AD (PS1 and APP mutations or trisomy 21), but such
an association would support a link between U1 snRNP
abnormalities and aberrant β-amyloid processing mecha-
nisms in AD.
Since we recently identified U1 snRNP components in
the insoluble fraction in sporadic AD [3], we first wanted
to determine whether U1 snRNPs were also localized to
the insoluble fraction in familial AD (FAD) cases. We
therefore compared the insoluble proteome from post-
mortem frontal cortex of 5 pathology free controls and 6
carriers of pathogenic PS1 mutations (Table 1) with mass
spectrometry followed by quantitative proteomic analysis.
In addition to the expected AD markers (tau, β-amyloidTable 1 Demographics
Control PMI Age of death ApoE
BLSA-1313 n/a 92 3/3
BLSA-1471 n/a 87 2/3
BLSA-1517 16 71 4/4
BLSA-2027 7 86 2/3
BLSA-2066 17 95 2/3
AD (PS-1):
E10-110 42 47 3/3
UW-24 3.5 46 n/a
UW-238 <24 51 n/a
UW-301 7 37 n/a
UW-304 <24 58 n/a
UW-328 17.5 44 n/a
AD (APP):
E12-24 5.5 54 3/3
UW-16514 n/a 72 n/a
Down:
1 20 40 n/a
2 8 44 n/a
3 3 46 n/a
4 5 47 n/a
5 4.5 59 n/a
6 15 60 n/a
n/a not available; BLSA Baltimore longitudinal study of aging; E Emory; UW Universiand apolipoprotein E) and more recently AD-associated
collagen type XXV [13], the heat map of extracted ion in-
tensities (XIC, normalized protein intensities based on
raw signal to noise ratio) [14,15] demonstrated significant
enrichment of U1-70k and Sm-D2 in the FAD insoluble
fraction (Figure 1). Sm-B, Sm-D1, and other RNA pro-
cessing components were also enriched but did not
meet statistical significance (p < 0.05; Additional file 1:
Table S1). Of the many snRNPs in the brain, the U1 asso-
ciated snRNPs in Figure 1 were the only ones sequenced
in the FAD insoluble fractions. Sm-B and Sm-D isoforms
are not exclusive to the U1 snRNP, but thus far we do not
have evidence for the involvement of other U complexes
in this pathologic process [3]. We also compared the
enrichment of snRNPs (Additional file 1: Table S1) in the
insoluble fraction for FAD (Additional file 1: Table S1)
with our previous findings in sporadic AD cases [3].
U1-70k remained highly enriched in both datasets and, as
seen previously in sporadic AD cases [3], protein blotting
confirmed U1-70k enrichment in the PS1 insoluble prep-
aration (Figure 1).
To examine early onset genetic AD brain tissues for
evidence of U1 snRNP cytoplasmic aggregates similar to
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ty of Washington; Down syndrome cases from Rush University.
Figure 1 U1 snRNPs enriched in PS1 insoluble proteome. (A) Heat map showing quantitative proteomics of frontal cortex from 5 pathology
free controls and 6 carriers of pathogenic PS1 mutations (insoluble fraction) demonstrated enrichment (yellow color) of RNA splicing factors and
other AD associated proteins in PS1 mutation carriers (FAD-PS1). Log2 of mean of the extracted ion intensities (XIC; normalized protein intensities
based on raw signal to noise ratio; Additional file 1: Table S1) in the insoluble fraction from individual cases are shown. (B) Western blot showing
insoluble U1-70k in two sporadic (sAD) and two control cases with calnexin loading control. (C) Western blot showing insoluble U1-70k in 6 PS1
mutation carriers with α-tubulin as loading control.
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localize U1 snRNP in human PS1 and APP pathogenic
mutation carriers. We also examined Down syndrome
(DS, trisomy 21) cases as patients with DS have an extra
copy of amyloid precursor protein and invariably de-
velop Alzheimer’s disease later in life. U1-70k-labeled
neurofibrillary structures were observed in the cyto-
plasm of cortical neurons in most genetic AD cases
(PS1, 5/8; APP, 2/2; DS, 5/6; Figure 2). Although Sm-D1
only showed a trend for biochemical enrichment in the
FAD insoluble proteome (Figure 1; Additional file 1:
Table S1), Sm-D1 immunoreactivity was strongly associ-
ated with tangle-like structures in all cases (PS1-6/6,
APP-2/2, Down 6/6) (Figure 2). In contrast to our obser-
vations in sporadic AD cases [3], U1-A maintained a
normal nuclear distribution in genetic AD cases with
only rare U1-A tangle structures observed in some
Down syndrome cases. β-amyloid positive plaques and
hyperphosphorylated tau positive neurofibrillary tangles
are shown for reference.
The formation of PHF in AD has been recognized for
decades [16-18], and we previously employed dual im-
munofluorescence microscopy to demonstrate overlap of
U1-70k and tau-positive tangles [3]. We sought to obtain
more precise definition of the localization of snRNP ag-
gregates in FAD by immunoelectron microscopy. We
performed U1-70k and Sm-D1 immunogold staining
followed by silver enhancement and transmission elec-
tron microscopy in frontal cortex from an APP mutation
carrier (Figure 3). In addition to the expected nuclear
localization, U1-70k also labeled cytoplasmic fibrils, and
staining of adjacent sections demonstrated Sm-D1 and
AT8 labeling of morphologically similar structures with
characteristic periodicity of ~80 nm. These findingsconfirm a close association between the snRNP U1-70k
and Sm-D1 and pathological aggregates of tau in PHF.
We also examined U1-70k immunoelectron microscopy
in a PSEN1 mutation carrier (E10-110), however the
immunogold staining did not work well and yielded im-
ages of poor quality. We were otherwise limited by tissue
availability and quality for other FAD cases and did not
have sufficient tissues to perform EM in the Down syn-
drome cases. Because of the pathologic similarities ob-
served in the immunohistochemistry, we did not feel
that pursuing more immunoelectron microscopy experi-
ments would provide additional strength to the study.
Discussion
The pathologic aggregation of proteins is a hallmark of
neurodegeneration, and further characterization of these
components may provide insights into disease mecha-
nisms. Our recent discovery of U1 snRNP aggregates
and reduced RNA splicing efficiency in sporadic AD
brains suggests a potential novel mechanism of disease
pathogenesis [3]. Our new findings support and extend
our previous work by demonstrating the aggregation of
U1 snRNPs in cortex of individuals with early onset ge-
netic forms of AD. These findings suggest that snRNP
aggregation is involved in the development of AD in
cases that are caused by genetically-defined abnorma-
lities in amyloid processing.
How could dysfunctional amyloid processing lead to
snRNP aggregation? The common thread between all
three genetic subtypes studied in this report (PS1 and
APP mutations and trisomy 21) is the relative overproduc-
tion of toxic β-amyloid either through altered APP clea-
vage or APP over-expression. The simplest explanation is
that β-amyloid, through a toxic gain of function, drives a
Figure 2 Immunohistochemistry of U1 snRNPs in FAD and Down syndrome. DAB immunohistochemistry staining of postmortem human
frontal cortex (50 μm free floating sections) from control, PS1 mutation carrier, APP mutation carrier, and Down syndrome patient with (A-D) U1-70k,
(E-H) Sm-D1, and (I-L) U1-A. Black arrows designate U1 snRNP tangle-like aggregates. (M-P) PHF and (Q-T) β-amyloid provided as reference
for other AD pathologies. Representative sections shown. Scale bar = 10 μm.
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to the downstream effects of β-amyloid on tau aggregation.
We have demonstrated a close relationship between U1
snRNP aggregates and tau positive neurofibrillary tangles
through dual-label immunofluorescence [3] and immu-
noelectron microscopy (Figure 3). Although snRNPs are
mainly found in the nucleus, they are first translated in
the cytoplasm and likely rely on cytoskeletal elements
including microtubules to reach the nuclear envelope
thereby placing tau and splicing components in close
association [19]. In addition, tau and various components
of the spliceosome undergo phosphorylation [20] perhaps
leading to coincidental localization in the course ofpathological post-translational modification. The temporal
sequence of tau and snRNP aggregate formation (i.e.,
which pathology occurs first) or whether the different
pathologies form independently, remain unknown. In our
recent publication [3], we tried to determine if U1 snRNPs
aggregated before tau. We studied snRNP aggregates in
sporadic AD cases across multiple brain regions and Braak
stages. Based on these studies, we did not appreciate ro-
bust appearance of snRNP pathologic aggregates in brain
regions devoid of tau pathology [3]. We also observed
examples of discordant distributions of snRNP aggregates
and tau tangles in certain brain regions, like the hip-
pocampus, suggesting the possibility that these are
Figure 3 U1-70k and Sm-D1 immunogold labeling of paired helical filaments in APP mutation carrier. Transmission electron microscopy
was performed on adjacent 50 μm vibratome free-floating sections from an APP mutation carrier following immunogold labeling with (A, D, G)
U1-70k, (B, E, H) Sm-D1 and (C, F, I) PHF. Silver enhancement was utilized to label ultrastructural features. Gold particles specifically labeled
filamentous structures with all 3 antibodies. N-nuclei, C-cytoplasm, L-lipofuscin granules, black arrows point to immuno-gold particles (D-I), black
arrowheads point to nuclear U1-70k (D). Contents of dashed box in A-C presented in D-F, respectively. Scale bar (A-C) 1 μm, (D-F) 0.2 μm,
(G-I) 0.1 μm.
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availability of tissues and regions with the rare early onset
genetic cases, we were not able to evaluate these issues in
the current study. Further studies are needed to clarify the
association between neurofibrillary tangles and snRNP ag-
gregates in AD.
A significant limitation for proteomics discovery and
validation is the availability of antibodies that will work
in multiple applications (IHC, protein blotting, etc.).
This can be especially challenging when using tissues
that may have been fixed for different lengths of time
(i.e. tissues with longer fixation can destroy antibody epi-
topes). For this study, we focused on U1-70k not only
because it was the snRNP with high insoluble enrich-
ment in sporadic AD [3] and the snRNP with the grea-
test fold change in the FAD cases (Additional file 1:
Table S1), but also because the U1-70k antibody workedwell in immunohistochemistry, immunoelectron micros-
copy and protein blotting. Although only showing a
trend for enrichment, we also focused on Sm-D1
because we found an ideal Sm-D1 antibody that labeled
snRNP pathologic aggregates. We attempted to immuno-
stain for other enriched snRNPs but were never confident
the antibodies (Additional file 2: Table S2) were working
consistently. Additional reagents will need to be generated
to further examine these other snRNPs.
Other limitations of this study include the relatively
small sample size for APP, PS1, and DS cases, factors
related to working with postmortem tissues. For ex-
ample, our mass spectrometric analysis focused on PS1
mutation cases, so differences in APP and DS cases may
have been missed. Nevertheless, we observed many simi-
larities in U1 snRNP abnormalities among sporadic and
genetic forms of AD. Conversely, in contrast to our
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a relative paucity of U1-A pathology in FAD cases. This
may represent a key difference between sporadic AD
and FAD, but understanding the significance of this ob-
servation will require further study. Overall, the results
presented in this study significantly extends our previous
work in sporadic AD and suggest that U1 snRNP aggre-
gates may play a role in the pathogenesis of all forms
of AD.
In summary, we have identified insoluble U1 snRNP ag-
gregates in early onset genetic forms of AD and further
characterized the ultrastructural localization of snRNP ac-
cumulations. These results suggest that aberrant amyloid
processing may directly or indirectly influences snRNP
localization and solubility. Further understanding the de-
velopment of U1 snRNP pathology and contribution of
RNA splicing dysfunction in AD may prove critical in our
understanding of AD pathogenesis and the identification
of novel therapeutic approaches.
Methods
Antibodies
A polyclonal rabbit U1-70K antibody was developed and
purified using synthetic peptides [3]. Commercial primary
antibodies used include: tau (AT8, Pierce-MN1020, Thermo
Fisher Scientific, Rockford, IL; 0.1 μg/ml), SmD1 (50940,
Abcam; 0.125 μg/ml), U1A (WH0006626M1, Sigma), and
β-amyloid (in-house monoclonal which recognizes amino
acids 1–16 of β-amyloid; clone 87-5H8; used at 1:1000).
Commercial secondary antibodies include biotinylated
goat anti-mouse (BA-9200, Vector Labs), biotinylated goat
anti-rabbit (BA-1000, Vector Labs), ultra small immuno-
gold goat anti-rabbit (800.011, Aurion), and ultra small
immunogold anti-mouse (800.022, Aurion).
Human tissues
Fresh frozen tissues for preparing brain homogenates
and formaldehyde or formalin fixed tissues for immu-
nohistochemistry staining and electron microscopy was
obtained from the Emory Alzheimer’s Disease Research
Center Neuropathology Core, Atlanta, Georgia, and
University of Washington Alzheimer’s Disease Research
Center Neuropathology Core, Seattle, Washington. The 5
pathology free controls were obtained from the Johns
Hopkins University Brain Resource Center and Baltimore
Longitudinal Study of Aging (BLSA) [21]. The Down syn-
drome cases were obtained from Rush University Medical
Center, Chicago, IL.
Mass spectrometry
Fifty micrograms of protein from the insoluble pellet of
5 AD pathology free human controls and 6 human pre-
senilin 1 mutation carriers were subject to dual mass-spectrometry analysis followed by quantitative proteomic
analysis as previously described [3,15,22].
Immunohistochemistry
Cryopreserved 50 μm free-floating sections from post-
mortem human frontal cortex from control, PS1 muta-
tion, APP mutation and DS cases were immunostained
and visualized with 3,3-diaminobenzidine solution (DAB,
Sigma, D4418) as previously described [3,23].
Electron microscopy
Electron microscopy was performed as previously des-
cribed [24,25] with use of a JEOL JEM-1400 transmis-
sion electron microscope.
Additional files
Additional file 1: Table S1. Extracted ion intensities (XIC) from dual
mass spectrometry of insoluble brain fraction from individual cases in 5
control and 6 FAD with PSEN1 mutations (left) and proteomic spectral
counts of pooled insoluble fractions from control and sAD cases in our
previously published dataset (right) [3]. The average fold change of
protein enrichment in FAD and sAD as compared to control within each
group is shown. Protein spectral counts are shown for the control/sAD
comparison instead of XIC values because the original proteomic
sequencing run was not optimized for obtaining XIC values.
Additional file 2: Table S2. Antibodies that did not function well in
immunohistochemistry or protein blotting to demonstrate snRNP
aggregates or specific protein enrichment.
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